A Test in Focus Archives - Insights https://news.mayocliniclabs.com/category/testing/test-in-focus/ Get the latest news and education from Mayo Clinic Laboratories Fri, 14 Feb 2025 18:27:30 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.2 Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. https://news.mayocliniclabs.com/2025/01/21/assay-identifies-most-known-membranous-nephropathy-antigens-sanjeev-sethi-m-d-ph-d/ https://news.mayocliniclabs.com/2025/01/21/assay-identifies-most-known-membranous-nephropathy-antigens-sanjeev-sethi-m-d-ph-d/#respond Tue, 21 Jan 2025 14:00:00 +0000 https://news.mayocliniclabs.com/?p=113161 Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D.Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

The post Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. appeared first on Insights.

]]> https://news.mayocliniclabs.com/2025/01/21/assay-identifies-most-known-membranous-nephropathy-antigens-sanjeev-sethi-m-d-ph-d/feed/ 0 Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC https://news.mayocliniclabs.com/2024/09/24/unique-test-screens-for-recently-identified-peripheral-neuropathy-matthew-schultz-ph-d-and-amy-white-m-s-cgc/ https://news.mayocliniclabs.com/2024/09/24/unique-test-screens-for-recently-identified-peripheral-neuropathy-matthew-schultz-ph-d-and-amy-white-m-s-cgc/#respond Tue, 24 Sep 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=112496 Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGCMatthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

The post Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/09/24/unique-test-screens-for-recently-identified-peripheral-neuropathy-matthew-schultz-ph-d-and-amy-white-m-s-cgc/feed/ 0 Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S. https://news.mayocliniclabs.com/2024/09/17/panel-detects-demyelinating-neuropathy-biomarkers-john-mills-ph-d-and-divyanshu-dubey-m-b-b-s/ https://news.mayocliniclabs.com/2024/09/17/panel-detects-demyelinating-neuropathy-biomarkers-john-mills-ph-d-and-divyanshu-dubey-m-b-b-s/#respond Tue, 17 Sep 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=111225 Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

The post Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S. appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/09/17/panel-detects-demyelinating-neuropathy-biomarkers-john-mills-ph-d-and-divyanshu-dubey-m-b-b-s/feed/ 0 Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. https://news.mayocliniclabs.com/2024/09/10/genetic-tests-identify-risk-of-fluoropyrimidine-induced-toxicity-ann-moyer-m-d-ph-d/ https://news.mayocliniclabs.com/2024/09/10/genetic-tests-identify-risk-of-fluoropyrimidine-induced-toxicity-ann-moyer-m-d-ph-d/#respond Tue, 10 Sep 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=112060 Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

The post Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/09/10/genetic-tests-identify-risk-of-fluoropyrimidine-induced-toxicity-ann-moyer-m-d-ph-d/feed/ 0 Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D. https://news.mayocliniclabs.com/2024/08/06/panel-boosts-therapeutic-monitoring-of-ibd-drug-maria-alice-willrich-ph-d-and-melissa-snyder-ph-d/ https://news.mayocliniclabs.com/2024/08/06/panel-boosts-therapeutic-monitoring-of-ibd-drug-maria-alice-willrich-ph-d-and-melissa-snyder-ph-d/#respond Tue, 06 Aug 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=111980 Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D.Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.

The post Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D. appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/08/06/panel-boosts-therapeutic-monitoring-of-ibd-drug-maria-alice-willrich-ph-d-and-melissa-snyder-ph-d/feed/ 0 Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D. https://news.mayocliniclabs.com/2024/06/11/updates-streamline-autoimmune-neurology-testing-anastasia-zekeridou-m-d-ph-d/ https://news.mayocliniclabs.com/2024/06/11/updates-streamline-autoimmune-neurology-testing-anastasia-zekeridou-m-d-ph-d/#comments Tue, 11 Jun 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=111446 Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D.Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.

The post Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D. appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/06/11/updates-streamline-autoimmune-neurology-testing-anastasia-zekeridou-m-d-ph-d/feed/ 2 Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S. https://news.mayocliniclabs.com/2024/06/04/tests-aid-diagnosis-of-cancer-associated-neurological-disorders-divyanshu-dubey-m-b-b-s/ https://news.mayocliniclabs.com/2024/06/04/tests-aid-diagnosis-of-cancer-associated-neurological-disorders-divyanshu-dubey-m-b-b-s/#comments Tue, 04 Jun 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=111323 Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S.Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.

The post Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S. appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/06/04/tests-aid-diagnosis-of-cancer-associated-neurological-disorders-divyanshu-dubey-m-b-b-s/feed/ 2 New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. https://news.mayocliniclabs.com/2024/05/14/new-panels-help-find-cause-of-rapidly-progressive-dementia-greggory-gregg-day-m-d/ https://news.mayocliniclabs.com/2024/05/14/new-panels-help-find-cause-of-rapidly-progressive-dementia-greggory-gregg-day-m-d/#respond Tue, 14 May 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=106059 New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D.Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.

The post New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/05/14/new-panels-help-find-cause-of-rapidly-progressive-dementia-greggory-gregg-day-m-d/feed/ 0 Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D. https://news.mayocliniclabs.com/2024/04/30/assay-provides-quick-diagnosis-of-vexas-syndrome-david-s-viswanatha-m-d/ https://news.mayocliniclabs.com/2024/04/30/assay-provides-quick-diagnosis-of-vexas-syndrome-david-s-viswanatha-m-d/#respond Tue, 30 Apr 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=110290 Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

The post Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D. appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/04/30/assay-provides-quick-diagnosis-of-vexas-syndrome-david-s-viswanatha-m-d/feed/ 0 Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. https://news.mayocliniclabs.com/2024/04/23/assay-identifies-patients-eligible-for-new-ovarian-cancer-drug-maryam-shahi-m-d/ https://news.mayocliniclabs.com/2024/04/23/assay-identifies-patients-eligible-for-new-ovarian-cancer-drug-maryam-shahi-m-d/#respond Tue, 23 Apr 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=109931 Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

The post Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/04/23/assay-identifies-patients-eligible-for-new-ovarian-cancer-drug-maryam-shahi-m-d/feed/ 0